|Bid||77.01 x 900|
|Ask||77.20 x 1400|
|Day's Range||75.96 - 77.07|
|52 Week Range||60.32 - 80.74|
|Beta (3Y Monthly)||0.83|
|PE Ratio (TTM)||52.23|
|Forward Dividend & Yield||1.28 (1.61%)|
|1y Target Est||N/A|
- Late-breaking data for Abbott's investigational clip-based tricuspid heart valve repair system presented at EuroPCR - Data suggest the first-of-its-kind device reduces difficult-to-treat tricuspid regurgitation ...
ABBOTT PARK, Ill., May 16, 2019 /PRNewswire/ -- You don't need to follow #TransformationTuesday on Instagram or read the latest pop culture magazine to know that nearly half of Americans are trying to lose weight.1 The ketogenic or "keto" diet – a high fat, moderate protein and very low carbohydrate eating pattern – is proven to be an effective weight management plan when followed correctly,2 yet not all keto products on the market have the right ratio of macronutrients ("macros") to yield the best results. To address this need, Abbott (ABT) is launching new ZonePerfect® Keto made with 75% fat, 20% protein and 5% carbs.
ABBOTT PARK, Ill., May 15, 2019 /PRNewswire/ -- Student loan debt – affecting 1 in 4 Americans and topping $1.5 trillion – is one of the most pressing concerns of students graduating college this spring. Nearly 70% of graduates today have taken out a loan – and a recent survey of college students shows that 9 out of 10 of them are on the hunt for a company with a student loan perk.
ABBOTT PARK, Ill., May 14, 2019 /PRNewswire/ -- Abbott (ABT) today announced that it has partnered with the National Institutes of Health (NIH) on the BRAIN (Brain Research through Advancing Innovative Neurotechnologies) initiative to accelerate advancements in neuroscience research. As part of the agreement, Abbott will provide the company's neuromodulation technologies—including directional deep brain stimulation (DBS), spinal cord stimulation (SCS), and dorsal root ganglion (DRG) therapy—for research related to these NIH initiatives to explore their application for chronic pain and progressive movement disorders, like Parkinson's disease.
ABBOTT PARK, Ill., May 7, 2019 /PRNewswire/ -- Abbott (NYSE: ABT) will present at the UBS Global Healthcare Conference on Tuesday, May 21, 2019 . Brian Yoor , executive vice president of finance and chief ...
ABBOTT PARK, Ill., May 6, 2019 /PRNewswire/ -- Abbott today announced the launch of a new, smarter heart monitor for better arrhythmia detection—positive news for people at risk for irregular heartbeats. Now with CE Mark in Europe and U.S. Food and Drug Administration (FDA) clearance, the next-generation Confirm Rx™ insertable cardiac monitor (ICM), a paperclip-sized implantable device, combines smartphone connectivity and continuous, remote monitoring to track unpredictable heart rhythm problems for fast and accurate diagnosis.
- WHO Prequalification approval allows Abbott to bring critical technology to more resource-limited settings - Confirms that the m-PIMA™ HIV-1/2 VL meets global standards of quality, safety and efficacy ...
ABBOTT PARK, Ill., April 30, 2019 /PRNewswire/ -- Abbott (ABT) today announced the next phase of partnership with the U.S. Department of Defense (DoD) and researchers from the Transforming Research and Clinical Knowledge in Traumatic Brain Injury (TRACK-TBI) Network, one of the largest traumatic brain injury (TBI) efforts of its kind. "Traumatic brain injury is a significant health issue affecting both active Service Members and Veterans, and we are committed to developing solutions for those impacted by brain injury," said Krista Caudle, Ph.D., project manager, Neurotrauma and Psychological Health Project Management Office, U.S. Army Medical Materiel Development Activity (USAMMDA).
ABBOTT PARK, Ill., April 29, 2019 /PRNewswire/ -- Abbott (ABT) announced today that a new study published in Circulation found its High Sensitive Troponin-I blood test could predict the chance of developing a cardiac event years before it occurs in people with no symptoms when added to current heart disease assessments.1 Using data from the Atherosclerosis Risk in Communities (ARIC) study, researchers suggest doctors could add the test to routine physical assessments in healthy middle-aged and older adults to better predict their chances of developing heart disease.
- Sales and EPS growth exceed guidance; projects strong full-year outlook - Long-term growth drivers - including FreeStyle Libre, MitraClip and Alinity - achieved strong double-digit growth - Reported ...
ABBOTT PARK, Ill., April 11, 2019 /PRNewswire/ -- Abbott (ABT) and its foundation, the Abbott Fund, are providing more than $500,000 in grants and healthcare products to support relief efforts for Cyclone Idai in Southeast Africa, including Mozambique, Malawi and Zimbabwe. According to the United Nations, significant aid is needed to help meet immediate needs across the region, following the devastating impact of Cyclone Idai and continued heavy rains and flooding. This includes focused efforts in Mozambique to address cholera, malaria and other diseases, as well as to meet immediate needs for food, water, shelter and medical care across the region.
ABBOTT PARK, Ill., March 20, 2019 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its first-quarter 2019 financial results on Wednesday, April 17, 2019 , before the market opens. The announcement will ...
This new technology will help keep up with the growing demand for infectious disease testing. Alinity m will provide unprecedented flexibility in molecular diagnostic testing, allowing more tests to be done in shorter timeframes, while reducing the space and number of instruments needed to conduct large amounts of tests.
NEW ORLEANS, March 17, 2019 /PRNewswire/ -- Abbott (ABT) today announced new late-breaking data from the MOMENTUM 3 study, the world's largest randomized controlled trial to assess outcomes in patients receiving a heart pump to treat advanced heart failure. In reviewing data across the complete 1,028 patient cohort, MOMENTUM 3 met its primary endpoint of event free survival while showcasing improved rates of overall survival, quality of life and a reduction in adverse events with the HeartMate 3™ left ventricular assist device (LVAD).
NEW ORLEANS, March 17, 2019 /PRNewswire/ -- Abbott (ABT) today announced positive late-breaking data from two separate analyses of the COAPT™ Trial showing additional key benefits from treatment with MitraClip™ for heart failure patients with clinically significant secondary (or functional) mitral regurgitation (MR), or leaky heart valve. Both data sets were presented today at the American College of Cardiology's (ACC) 68th Annual Scientific Session.
ABBOTT PARK, Ill., March 14, 2019 /PRNewswire/ -- Abbott (ABT) today announced it received approval from the U.S. Food and Drug Administration (FDA) for a new, expanded indication to its leading MitraClip™ device used to repair a leaky mitral valve without open-heart surgery.
- Five late-breaking data presentations at ACC 2019 showcase the breadth and depth of Abbott's cardiovascular portfolio - New late-breaking data highlight outcomes for key Abbott cardiovascular technologies: ...
NEW YORK, Feb. 27, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
ABBOTT PARK, Ill., Feb. 25, 2019 /PRNewswire/ -- Abbott (NYSE: ABT) will present at the Barclays Global Healthcare Conference on Wednesday, March 13, 2019 . Brian Yoor , executive vice president of finance ...
ABBOTT PARK, Ill., Feb. 22, 2019 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 32 cents per share. This marks the 381 st consecutive quarterly ...
- Data presented at ATTD confirms previous analyses that higher rates of scanning with the FreeStyle Libre system are strongly associated with improved glucose control - Prolonged hypoglycemia reduced ...
ABBOTT PARK, Ill. and BAGSVÆRD, Denmark, Feb. 20, 2019 /PRNewswire/ -- Abbott (ABT) and Novo Nordisk today announced a non-exclusive partnership that will integrate insulin dose data from Novo Nordisk pre-filled and durable connected pens directly into the digital health tools compatible with the FreeStyle Libre system (FreeStyle LibreLinkii mobile app and LibreViewiii cloud-based system). The partnership reflects both companies′ commitment to make diabetes management easier by connecting key technologies such as continuous glucose monitoring (CGM) and connected insulin pens.
ABBOTT PARK, Ill., Feb. 20, 2019 /PRNewswire/ -- Abbott (ABT) announced today it has received CE Mark for the world's most sensitive rapid diagnostic test for the detection of hepatitis B surface antigen, the Determine™ HBsAg 2 test for use with serum, plasma or whole blood.1,2,3 This highly sensitive, easy-to-use, rapid lateral flow test enables identification of those with the virus and facilitates linkage to care in every healthcare setting.
NEW YORK, NY / ACCESSWIRE / January 23, 2019 / U.S. markets declined on Tuesday, breaking a streak of four consecutive days in the green, on growing trade concerns. Stocks were pressured lower on reports ...
- Full-year 2018 sales growth of 11.6 percent; organic sales growth of 7.3 percent - Issues financial outlook for 2019, reflecting double-digit EPS growth and 6.5 to 7.5 percent organic sales growth ABBOTT ...